Details of the Drug

General Information of Drug (ID: DMT4FI5)

Drug Name

SAR-566658

Synonyms

CA6-targeted DM4 immunotoxin (cancer), sanofi-aventis; DM4-conjugated DS6 MAb (cancer), sanofi-aventis; DM4-conjugated anti-Muc1 monoclonal antibody (cancer), sanofi-aventis

Indication

Disease Entry	ICD 11	Status	REF
Triple negative breast cancer	2C60-2C65	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

TTD ID: D0G5YR

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mucin-1 (MUC1)	TTBHFYQ	MUC1_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Triple negative breast cancer

ICD Disease Classification

2C60-2C65

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Mucin-1 (MUC1)	DTT	MUC1	4.59E-01	-0.07	-0.41

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01156870) First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor. U.S. National Institutes of Health.
3	Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology.Molecular Cancer Therapeutics. 11/2011; 10(Supplement 1):A73-A73.